Drugs / SENL101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06136364 | Aug 2023 → Aug 2024 overdue | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05398614 | May 2022 → Dec 2023 | T-cell acute lymphoblastic leukemia, T-cell non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-28 | Hebei Senlang Biotechnology Inc., Ltd. | Results 重磅预告｜森朗生物6项前沿成果即将亮相ASH2025 senlangbio.com ↗
其中，靶向CD7的CAR-T 细胞疗法 SENL101在治疗复发/难治性T-ALL/LBL患者的I期临床试验（CARMA-I研究）结果表现亮眼，展现出卓越的疗效和较同类产品更有临床优势的安全性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-28 | Hebei Senlang Biotechnology Inc., Ltd. | 重磅预告｜森朗生物6项前沿成果即将亮相ASH2025 senlangbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENL101 | “SENL101 Autologous T Cell Injection” NCT06136364 ↗ |
| Modality | Cell therapy | “Patients will be treated with CD7 CAR-T cells” NCT05398614 ↗ |
| Target | CD7 | “Patients will be treated with CD7 CAR-T cells” NCT05398614 ↗ |